Dr. Nancy Chang

Biography

Dr. Chang, the Founder, CEO and Chairman of Tanox, a successful US based Biotechnology Company known for its strong drug development capabilities and track record. Dr. Chang is currently the President of Apex Enterprise Inc., an investment management firm with focus on healthcare investments. Dr. Chang is also an adjunct professor at the Departments of Medicine and Genetics at Baylor College of Medicine. Dr. Chang was born in Taiwan. She received her Ph.D. from the Division of Medical Sciences of Harvard University in 1979. After graduation, Dr. Chang worked at the Roche Institute of Molecular Biology and was a member of the team who conducted pioneering research on recombinant alpha and beta interferons. Dr. Chang subsequently joined Centocor (now a Division of Johnson and Johnson) where she held several leadership positions in the development of antibody based diagnostic and therapeutic products. Dr. Chang is known for her pioneering research and development efforts in the HIV field. In 1986, Dr. Chang joined Baylor College of Medicine as an Associate Professor at the Department of Virology and later she founded Tanox, Inc. Tanox successfully developed the breakthrough drug Xolair which was first approved by the US FDA in 2003 for treating patients with moderate to severe asthma. Now Xolair is also approved for treating atopic dermatitis and allergy in more than 30 countries worldwide. In addition to Xolair, four of Tanox products in the pipeline are now in late stage clinical development with promising results for treating patients with diseases including allergy, atopic dermatitis, HIV infection and age Macular degeneration, etc. Tanox was acquired by Genentech in 2007 for USD $919 million. Dr. Chang has served on the board of directors of several enterprises including: the Federal Reserve Bank in Houston, Project Hope, BioHouston, Charles River Laboratories, the Board of Visitors of the University of Texas, M.D. Anderson Cancer Center and the Asia Society. Her scientific publication includes over 35 papers at peers reviewed journals including Nature and Science on topics including monoclonal antibodies and HIV. She has also been awarded nine patents including the first US patent in the HIV field. Dr. Chang, the Founder, CEO and Chairman of Tanox, a successful US based Biotechnology Company known for its strong drug development capabilities and track record. Dr. Chang is currently the President of Apex Enterprise Inc., an investment management firm with focus on healthcare investments. Dr. Chang is also an adjunct professor at the Departments of Medicine and Genetics at Baylor College of Medicine. Dr. Chang was born in Taiwan. She received her Ph.D. from the Division of Medical Sciences of Harvard University in 1979. After graduation, Dr. Chang worked at the Roche Institute of Molecular Biology and was a member of the team who conducted pioneering research on recombinant alpha and beta interferons. Dr. Chang subsequently joined Centocor (now a Division of Johnson and Johnson) where she held several leadership positions in the development of antibody based diagnostic and therapeutic products. Dr. Chang is known for her pioneering research and development efforts in the HIV field. In 1986, Dr. Chang joined Baylor College of Medicine as an Associate Professor at the Department of Virology and later she founded Tanox, Inc. Tanox successfully developed the breakthrough drug Xolair which was first approved by the US FDA in 2003 for treating patients with moderate to severe asthma. Now Xolair is also approved for treating atopic dermatitis and allergy in more than 30 countries worldwide. In addition to Xolair, four of Tanox products in the pipeline are now in late stage clinical development with promising results for treating patients with diseases including allergy, atopic dermatitis, HIV infection and age Macular degeneration, etc. Tanox was acquired by Genentech in 2007 for USD $919 million. Dr. Chang has served on the board of directors of several enterprises including: the Federal Reserve Bank in Houston, Project Hope, BioHouston, Charles River Laboratories, the Board of Visitors of the University of Texas, M.D. Anderson Cancer Center and the Asia Society. Her scientific publication includes over 35 papers at peers reviewed journals including Nature and Science on topics including monoclonal antibodies and HIV. She has also been awarded nine patents including the first US patent in the HIV field.

Research Interest

Medical Sciences